676594-38-0

JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC50 value of 2.2, 21.4, 1.8 μM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease[1].

ChEBI: Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate is a carboxamide resulting from the formal condensation of the carboxy group of 2-thienylacetic acid with the amino group of methyl 3-aminothiophene-2-carboxylate. It is a selective inhibitor of c-Jun N-terminal kinases (JNKs). It has a role as a c-Jun N-terminal kinase inhibitor. It is a methyl ester, a member of thiophenes and a secondary carboxamide. It is functionally related to a 2-thienylacetic acid.

JNK1: 1.8 μM (IC₅₀); JNK3: 2.2 μM (IC₅₀); JNK2: 21.4 μM (IC₅₀)

[1] Hom RK, et al. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett. 2010 Dec 15;20(24):7303-7. DOI:10.1016/j.bmcl.2010.10.066